Atorvastatin

A comprehensive safety analysis pooling data from 21 completed and 23 ongoing clinical trials involving 4,271 patients (1,845 patient-years of exposure) found that persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.7% of patients treated with atorvastatin at dosages of 10-80 mg/day.

The LODESTAR clinical trial involving 4,400 adults (average age 65 years) with coronary artery disease compared rosuvastatin and atorvastatin over 3 years, finding no significant differences between the two statins for all-cause death, heart attack, stroke, or revascularization rates.

A comprehensive safety analysis pooling data from 21 completed and 23 ongoing clinical trials involving 4,271 patients (1,845 patient-years of exposure) found that persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.7% of patients treated with atorvastatin at dosages of 10-80 mg/day.

A 4-week study of 21 healthy individuals aged 25-63 receiving moderate-dose atorvastatin (20 mg/day) demonstrated significant reductions in total cholesterol, LDL-cholesterol, non-HDL-cholesterol, and triglycerides, but also showed elevated plasma liver enzymes (AST, ALT, CK, LDH) and no significant effects on matrix metalloproteinase levels.

A comprehensive safety analysis pooling data from 21 completed and 23 ongoing clinical trials involving 4,271 patients (1,845 patient-years of exposure) found that persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.7% of patients treated with atorvastatin at dosages of 10-80 mg/day.

A comprehensive safety analysis pooling data from 21 completed and 23 ongoing clinical trials involving 4,271 patients (1,845 patient-years of exposure) found that persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.7% of patients treated with atorvastatin at dosages of 10-80 mg/day.